FDA panel to consider brain stimulator for epilepsy

by Barbara Bronson Gray, Healthday Reporter
FDA panel to consider brain stimulator for epilepsy
Implantable device pre-empts seizures, device maker says.

(HealthDay News) - A U.S. Food and Drug Administration advisory panel will weigh on Friday the merits of a new therapy for some people with epilepsy who have seizures that don't respond to medication.

Smaller and thinner than an implantable defibrillator, the battery-powered, programmable device, called the RNS System, is placed just under the skull during surgery. Electrodes reach from the device to the one or two places in the patient's brain that create the that causes seizures. The device works by short-circuiting in that area to normalize before a seizure is triggered.

"This is the first responsive neuro-stimulation system ever designed," said Frank Fischer, president and CEO of Mountain View Calif.-based NeuroPace Inc., which developed the device. "Our long-term results show that patients have a reduction of 50 percent or more in their , compared to baseline, and a lessening of seizure severity."

The device is designed specifically for people aged 18 and older with partial-onset epilepsy, which occurs when one or more fixed locations in a person's brain start the cascade of nerve firing that creates a seizure.

NeuroPace has done two studies involving a total of 256 patients who were monitored for a period of between two and nine years, without any significant problems, according to Fischer.

Epilepsy is a brain disorder in which a person suffers repeated seizures over time.

It affects more than 2 million Americans, according to the Epilepsy Foundation, making it the third most common in the United States, after Alzheimer's and stroke. Seizures are episodes of disturbed brain activity that cause changes in attention or behavior. keep firing instead of acting in an organized way. The malfunctioning electrical system of the brain causes surges of energy that can cause a person to have muscle contractions or to black out.

Physicians can modify the programming of the device even after it has been implanted, to reflect a patient's needs over time, Fischer said. They can also observe the brain activity of a patient from a laptop computer in their office—to help them manage a patient's treatment, he said.

On Friday, members of the FDA panel will listen to a presentation by NeuroPace and hear from members of the public; they will also ask specific questions of company officials.

By the end of the day, the panel is expected to vote on whether to recommend that the device be approved. The FDA does not have to follow the recommendations of its expert panels, but it typically does.

Representatives of the Epilepsy Foundation will also comment on the need for innovative treatments for the disease, but they will not speak for or against approval of the product.

"We're not in a position to evaluate everything that an evaluating committee would be looking at, but we do advocate for access to treatments once they're FDA-approved," explained Angela Ostrom, vice president of public policy and advocacy for the Epilepsy Foundation, based in Landover, Md.

While Fischer said it is too soon to say what the device might cost, comparable systems for heart problems range in price from $30,000 to $35,000, not including the cost of the surgery to implant the device. The battery that powers the device lasts about three years. When it fails, a new device has to be substituted in a 30-to-60-minute outpatient surgical procedure, Fischer said.

Fischer said the company has spent 15 years developing the device.

More information: For more on epilepsy, see the Epilepsy Foundation .

add to favorites email to friend print save as pdf

Related Stories

Epilepsy Patients Are Given New Hope With Brain Implant

Dec 09, 2009

(PhysOrg.com) -- A startup company, Neuropace in Mountain View Ca., has developed a device that offers new hope for epilepsy patients. The device is designed to neutralize the abnormal electrical activity ...

Recommended for you

How is depression related to dementia?

19 hours ago

A new study by neuropsychiatric researchers at Rush University Medical Center gives insight into the relationship between depression and dementia. The study is published in the July 30, 2014, online issue of Neurology, the me ...

Brainwaves can predict audience reaction

Jul 30, 2014

Media and marketing experts have long sought a reliable method of forecasting responses from the general population to future products and messages. According to a study conducted at The City College of New ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

INSeducate
not rated yet Feb 22, 2013
The International Neuromodulation Society offers downloadable fact sheets with extensive medical references about closed-loop neurostimulation systems, and other explanatory materials. Its 11th World Congress takes place June 8 - 13, 2013, in Berlin - with sessions on neurostimulation and epilepsy.